Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, about the October 6, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Altimmune, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - To participate in the class action, investors can submit a form or contact the law firm for more information [2][5] - The lawsuit claims that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, leading to investor damages when the true results were revealed [4] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [3] - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [3] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [3]

Core Viewpoint - Altimmune, Inc. is facing a class action lawsuit following the announcement of disappointing results from its IMPACT Phase 2b MASH trial of Pemvidutide, leading to a significant drop in its stock price [3][4]. Group 1: Company Overview - Altimmune, Inc. is a biopharmaceutical company involved in developing treatments for liver diseases, specifically targeting MASH (Metabolic Dysfunction-associated Steatotic Liver Disease) [3]. - The company reported topline results from the IMPACT Phase 2b MASH trial on June 26, 2025, which failed to meet statistical significance for its primary endpoint related to fibrosis reduction [3]. Group 2: Stock Performance - Following the announcement of the trial results, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in just one day [3]. Group 3: Legal Proceedings - The class period for the lawsuit is defined as August 10, 2023, to June 25, 2025, and shareholders are encouraged to register for potential recovery [3][4]. - The deadline for shareholders to seek lead plaintiff status is October 6, 2025, and there is no cost or obligation to participate in the case [4]. Group 4: Allegations - The complaint alleges that Altimmune provided inflated expectations regarding the trial results, which ultimately did not materialize due to a higher-than-expected placebo response [3]. - The company's response to the trial's failure was described as indifferent, attributing the results to the Phase 2 nature of the trial and expressing hope for better outcomes in the Phase 3 trial [3].

Core Viewpoint - Altimmune, Inc. is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between August 10, 2023, and June 25, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit was initiated following Altimmune's announcement on June 26, 2025, regarding the topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [2]. - The company's stock price experienced a significant decline of 53.2%, dropping from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, following the disappointing trial results [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until October 6, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

Company Overview - Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases [1] - The company's lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist targeting MASH, Alcohol Use Disorder (AUD), Alcohol-Associated Liver Disease (ALD), and obesity [1] Investor Engagement - Management will participate in several upcoming investor conferences, including the Wells Fargo Healthcare Conference on September 5, 2025, and the H.C. Wainwright Global Investment Conference on September 9, 2025 [3] - The Morgan Stanley Global Healthcare Conference is scheduled for September 10, 2025, where a fireside chat will take place [3] - These events will include one-on-one meetings and webcasts accessible via the Altimmune website [3]

Core Viewpoint - A class action securities lawsuit has been filed against Altimmune, Inc. due to alleged securities fraud affecting investors between August 10, 2023, and June 25, 2025 [1] Group 1: Lawsuit Details - The lawsuit follows a press release from Altimmune on June 26, 2025, announcing disappointing results from the IMPACT Phase 2b MASH trial of Pemvidutide, where the company failed to achieve statistical significance in the primary endpoint of fibrosis reduction [2] - The stock price of Altimmune plummeted by 53.2%, from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, following the announcement of the trial results [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 6, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4]

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. for alleged securities fraud and unlawful business practices following disappointing trial results [2][3]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Altimmune and its officers engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Altimmune securities during the Class Period have until October 6, 2025, to request to be appointed as Lead Plaintiff [3]. Group 2: Trial Results and Market Reaction - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in the primary endpoint of fibrosis reduction [3]. - The trial results showed a positive trend in fibrosis improvement, but a higher-than-expected placebo response led to the lack of statistical significance [3]. - Following the announcement, Altimmune's stock price fell by $4.10 per share, or 53.2%, closing at $3.61 per share [4].

Core Viewpoint - Altimmune, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between August 10, 2023, and June 25, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit was initiated following Altimmune's announcement on June 26, 2025, regarding the topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [2]. - The company's stock price experienced a significant decline of 53.2%, dropping from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, following the disappointing trial results [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until October 6, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. regarding allegations of securities fraud and unlawful business practices related to the company's performance and disclosures [2][4]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Altimmune and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Altimmune securities during the Class Period have until October 6, 2025, to request to be appointed as Lead Plaintiff [2]. Group 2: Company Performance - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in the primary endpoint of fibrosis reduction [4]. - The company had previously set inflated expectations for the trial results, but the analysis revealed a higher-than-expected placebo response that contributed to the failure [4]. - Following the announcement of the trial results, Altimmune's stock price fell by $4.10 per share, or 53.2%, closing at $3.61 per share [5].

Core Viewpoint - A class action lawsuit has been filed against Altimmune Inc. by Berger Montague on behalf of investors who acquired the company's securities during the specified class period from August 10, 2023, to June 25, 2025 [1][2]. Company Overview - Altimmune Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, focusing on therapeutics for obesity and liver disease, including MASH (metabolic dysfunction-associated steatohepatitis) [2]. Legal Action Details - Investors who purchased Altimmune securities during the class period have until October 6, 2025, to seek appointment as lead plaintiff representatives [2]. - The lawsuit follows a press release from Altimmune on June 26, 2025, announcing disappointing results from its IMPACT Phase 2b trial of Pemvidutide for MASH treatment, where the primary endpoint of fibrosis reduction did not achieve statistical significance [3]. Stock Price Impact - Following the announcement of the trial results, Altimmune's stock price plummeted by 53.2% in one day, dropping from a closing price of $7.71 on June 25, 2025, to $3.61 on June 26, 2025 [4].

Core Viewpoint - Altimmune, Inc. faced significant stock price decline following the announcement of disappointing results from its IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint analysis [1][2]. Group 1: Company Performance - The IMPACT Phase 2b MASH trial results were released on June 26, 2025, revealing that while there was a positive trend in fibrosis improvement, the results did not meet statistical significance due to a higher-than-expected placebo response [1]. - Following the announcement, Altimmune's stock price plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a dramatic decline of 53.2% in just one day [1]. Group 2: Legal Actions - Shareholders who purchased shares of Altimmune during the class period from August 10, 2023, to June 25, 2025, are encouraged to contact the Gross Law Firm regarding potential lead plaintiff appointments in a class action lawsuit [1][2]. - The deadline for shareholders to register for the class action and seek lead plaintiff status is October 6, 2025 [2]. Group 3: Firm's Commitment - The Gross Law Firm is dedicated to protecting the rights of investors affected by deceitful practices and aims to ensure companies adhere to responsible business practices [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that led to artificial inflation of stock prices [3].